


Brno Oncology Days
Nursing Conference

Conference Programme

12th–14th October 2022
Brno, Exhibition Centre, Hall E



www.onkologickedny.cz/en



NETWORKING BRINGS PROFESSIONALS TOGETHER

Join us in Brno and network with your colleagues, interact with key opinion leaders, ask questions and debate on burning topics in the field of medical oncology in a uniquely meaningful way.

See you at BOD 2023
November 1-3, 2023

CONTENT

Introduction	4
Conference plan	6

CONFERENCE PROGRAMME8

THURSDAY / R. WERNER HALL

Precision Medicine in Pediatric Oncology I, II	11
--	----

FRIDAY / J. BAKEŠ HALL

International Brno Oncology Day	12
Breaking News in Oncology 2022 – Current Treatment	
Standard	12
Genitourinary Tract Tumors	12
Meet the Experts (Young Oncologists Program)	12
Advances in Cancer Biology	12

FRIDAY / R. WERNER HALL

Patient-centred cancer care and survivorship I-III.....	14
---	----

INVITED SPEAKERS

Carmelo Rizzari	15
Michael Craig Cox.....	16
Stefaan Van Gool	17
Nicolas André	18
Suzanne Turner	19
Domen Ribnikar.....	20
Florian Lordick.....	21
Gerald Prager	22
Michal Mego	23
Jacqueline Loonen.....	24
Françoise Meunier	25
Karina Dahl Steffensen.....	26



INTRODUCTION

Dear colleagues, dear friends,

On behalf of the Masaryk Memorial Cancer Institute and the Organization committee, let me **welcome you to the 46th year of Brno Oncology Days and the 36th year of Nursing Conference**. Traditionally, the Brno Oncology days is the largest **specialists' event on oncology** in our country.

After the last few years, when we had to switch to partial of fully-online participation, it is a great pleasure to be back to present form and to see all of you in the hall of Congress Center Pavilion E at the Brno Exhibition Center. This year's BOD shall offer an extremely broad program for specialists, which includes over 80 sections of oral and poster presentations.

If you want specific numbers – a total of 361 contributions will be presented during this three-day conference. Out of these, 331 will be oral presentations, which will be grouped into 45 educational sessions and 12 free communications sessions.

For our permanent program, we would like to pay your attention to **Glio Meeting** on Wednesday, which is a multidisciplinary meeting of special-

lists working in diagnosis and treatment of brain tumors. Farther more, the **PharmAround** seminars are prepared for you again. Those seminars deal with problematics of clinical studies. It is impossible to omit the education seminars for **general practitioners and non-oncologists**. Apart from the traditional sessions on topics of onco-gynecology, tumors of gastrointestinal and urogenital tract, precision oncology and palliative care, two more sessions will be dedicated to early tumor detection, onco-plastic surgery, skin tumors, hereditary tumor syndromes, news in radionuclide diagnosis and therapy and numerous usages of artificial intelligence in oncology. For new colleagues, but not solely for them, there will be a special seminar on Communication of serious news in oncology and the Specifics of working with patients in the end of their lives.

As part of **Nursing Conference**, we will present possibilities on professional development of nurses, including new educational program Nursing Care in Oncology and Hematooncology. Farther on, there will be discussions on aspects of integration of healthcare professionals from Ukraine into local working teams and on methods of legal protection and defense against inadequate forms of behavior in healthcare.

For the second year in a row, we prepare for you the **International Brno Oncology Day (I-BOD)**; it will take place on **Friday, October 14th 2022**.



Radka Obermannová, MD, PhD.
Chairman of BOD and IBOD programme



PhDr. Jana Kocourková, MBA
Chairman of Nursing Conference programme

The basic idea behind an international oncology day is deepening of cooperation between specialists within Central European region. This year, several **leading specialists** have accepted our invitation along with young doctors and scientists from neighboring countries. This includes university centers in Vienna, Ljubljana, Bratislava and Leipzig.

Our broad program offers a wide scale of symposia including education sections on news from international ASCO and ESMO conferences and case-reports in **Meet the Experts**, which will include presentation of interesting cases done by young oncologists from the Czech Republic and the neighboring states. We truly believe that we will achieve a creative and pleasant academic environment that will support common work of experts in their interest fields, and also mutual cooperation between the emerging generation of young doctors and experts in translational research.

Additional two sections of the program are aimed at the main challenges of Europe's Beating Cancer Plan, namely **Patient-centred cancer care and Survivorship and precision medicine in pediatric oncology**. These sections will take place under the auspices of the Government of the Czech Republic on the occasion of Czech Presidency in the EU Council.



A handwritten signature in black ink, appearing to read 'J. Sedo'.

Jiří Šedo, MD, PhD.
Chairman of organization committee



A handwritten signature in black ink, appearing to read 'M. Svoboda'.

Prof. Marek Svoboda, MD, PhD.
General Director of Masaryk Memorial Cancer Institute

Guarantorship over the Brno Oncology Days is provided by the Czech Society for Oncology by Czech Medical Association of J. E. Purkyně, and several professional societies including the European Society for Clinical Oncology (ESMO).

We were always pleased that the conferences are highly professional, but also offer pleasant social events for their participants – an event where colleagues and friends could be met. This year is not different: you are invited to a **festive evening** that will include handing over of prizes and a launch of a book.

Finally, we would like to thank to all sponsors and all exhibitors for their financial support. An event of this magnitude could not have been created and managed successfully without them.

After the conference ends, a complete video archive from all the main halls of the conference will be available on the website for registered participants.

We wish you to have a great time and look forward to meeting you!


BRNO EXHIBITION CENTRE




Brno, Křížkovského street, hall E




2nd floor



1st floor



ground floor



WEDNESDAY (12th OCTOBER 2022)

	Brno Oncology Days			
	J. Bakeš Hall	J. Šprindrich Hall	R. Werner Hall	L. Bakešová Hall
REGISTRATION OPEN FROM 8.00 AM				
OPENING CEREMONY 8.45 AM				
9.00–10.30	Lung Cancer and Head and Neck Cancer (free communications)	Molecular Diagnostics and Modern Cancer Therapy (free communications)	Varia (free communications)	Educational Session Clinical Pharmacist and his Cooperation with Oncologist
COFFEE BREAK (10.30–10.40)				
10.40–12.10	Educational Session Lung Cancer: Diagnostics and Treatment in the CR	Radiotherapy (free communications)	Educational Session Advances in Systemic Treatment of Skin Tumors	Educational Session Hereditary Cancer Diseases
LUNCH (12.10–13.00)				
13.00–13.50	Satellite Symposium Amgen	Satellite Symposium Novartis	Satellite Symposium MSD	
BREAK (14.00–14.10)				
14.10–15.40	PharmAround / CzECRIN I Workshop	Glio Meeting 2022 I	Educational Session Malignant Gynecologic Tumors	Educational Symposium for General Practitioners and Non-oncologists I
COFFEE BREAK (15.40–15.50)				
15.50–17.20	Educational Session Molecular Tumor Board or To whom, when and where to Provide Consultation?	Glio Meeting 2022 II	Breast Carcinoma (free communications)	Educational Symposium for General Practitioners and Non-oncologists II
BREAK (17.20–17.30)				
17.30–19.00	Satellite Symposium BMS	Glio Meeting 2022 III	Translational Cancer Research in Practice (free communications)	Educational Symposium for General Practitioners and Non-oncologists III
END OF THE FIRST DAY (19.00)				

THURSDAY (13th OCTOBER 2022)

	Brno Oncology Days		
	J. Bakeš Hall	J. Šprindrich Hall	R. Werner Hall
7.40–8.30	Satellite Symposium Pfizer		
COFFEE BREAK (8.30–8.45)			
8.45–10.15	Educational Session Breast Cancer I	Educational Session National Cancer Information System	Oncosurgery and Reconstruction Surgery (free communications)
BREAK (10.15–10.30)			
10.30–12.00	Educational Session Breast Cancer II	Educational Session Current Trends in Stereotactic Body Radiation Therapy	Educational Session Controversy in Gastric and Gastroesophageal Junction Cancer Surgery
LUNCH (12.00–13.00)			
13.00–13.50	Satellite Symposium Servier	Satellite Symposium Pfizer	Satellite Symposium Eli Lilly
BREAK (13.50–14.15)			
14.15–15.45	Educational Session Gastric and Gastroesophageal Junction Cancers	Educational Session Diagnostic and Treatment of NET – Nuclear Medicine Methods	Precision Medicine in Pediatric Oncology I
COFFEE BREAK (15.45–16.00)			
16.00–17.30	Educational Session Neoadjuvant Treatment of Primary Operable or Borderline Operable Pancreatic Cancer	Genitourinary and Gynecologic Tumours (free communications)	Precision Medicine in Pediatric Oncology II (16.00–17.45)
BREAK (17.30–17.40)			
17.40–18.40	Case Reports (free communications)	Systemic and Supportive Therapy (free communications)	
GALA DINNER WITH THE ANNOUNCEMENT OF COMPETITION WINNERS AND BOOK LAUNCH (19.30–24.00)			

FRIDAY (14th OCTOBER 2022)

	International Brno Oncology Day / Brno Oncology Days		
	J. Bakeš Hall	J. Šprindrich Hall	R. Werner Hall
7.30–8.30		Satellite Symposium Gilead	Working Group Educational Meeting Nutritional Care in Oncology
OPENING CEREMONY (8.30–8.50)			
8.50–10.20	IBOD Breaking News in Oncology 2022 – Current Treatment Standard	Educational Session Treatment Algorithm of Locally Advanced Rectal Cancer	Patient-Centred Cancer Care and Survivorship I
BREAK (10.20–10.30)			
10.30–12.00	IBOD Genitourinary Tract Tumors	Early Detection and Comprehensive Care Programs for Selected Cancer Types	Patient-Centred Cancer Care and Survivorship II
LUNCH (12.00–13.00)			
13.00–14.30	IBOD Meet the Experts (Young Oncologists Program)	Educational Session Specialized Palliative Care in the CR in 2022	Patient-Centred Cancer Care and Survivorship III (13.00–15.00)
COFFEE BREAK (14.30–14.45)			
14.45–16.15	IBOD Advances in Cancer Biology	Artificial Intelligence in Oncology (free communications)	

R. WERNER HALL / THURSDAY 13th OCTOBER 2022**14:15–15:45 PRECISION MEDICINE IN PEDIATRIC ONCOLOGY I**

Chairs: C. Rizzari, J. Štěřba, J. Gojo, S. Van Gool, M. Cox (Milano, Brno, Vienna, Cologne, Brisbane)

14:15 PRECISION PEDIATRIC ONCOLOGY

C. Rizzari (Milano)

14:25 PRECISION PEDIATRIC NEUROONCOLOGY

J. Gojo (Vienna)

14:40 PRECISION MEDICINE IN PEDIATRIC NEUROONCOLOGY

D. Sumerauer, L. Krsková, A. Vícha, K. Trková, V. Beneš, M. Kynčl, J. Zámečník, L. Šrámková, M. Zápotocký (Praha)

14:55 GENE FUSION PROTEINS AS THERAPEUTIC TARGETS IN PEDIATRIC ONCOLOGY

M. Cox (Brisbane)

15:10 ANTICANCER VACCINES IN PEDIATRIC ONCOLOGY

S. Van Gool (Cologne)

15:25 DENDRITIC CELL VACCINATION FOR R/R PEDIATRIC SOLID TUMORS IN BRNO

P. Múdry (Brno)

15:40 Discussion**15:45 Coffee break****16:00–17:45 PRECISION MEDICINE IN PEDIATRIC ONCOLOGY II**

Chairs: S. Turner, J. Štěřba, N. André, G. Klement (Cambridge, Brno, Marseille, Boston)

16:00 A REAL-WORLD GENOMICS-DRIVEN PRECISION MEDICINE IN PEDIATRIC ONCOLOGY

P. Pokorná, H. Pálová, S. Adamcová, V. Bystrý, M. Kýr, D. Al Tukmachí, S. Mejstříková, P. Múdry, J. Štěřba, O. Slabý (Brno)

16:15 PRECISION MEDICINE IN PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA

L. Šrámková, M. Žaliová, J. Domanský, Z. Novák, P. Sedláček, O. Hrušák, J. Trka, T. Votava, T. Kuhn, J. Starý (Praha, Brno, Olomouc, Plzeň, Ostrava)

16:30 LIQUID BIOPSIES IN EXTRA-CRANIAL SOLID TUMORS AS AN INTEGRAL PART OF PRECISION ONCOLOGY

N. André (Marseille)

16:45 CLINICAL APPLICATION OF TRANSCRIPTOMICS AND ITS INTEGRATION TO PRECISION ONCOLOGY

G. Klement (Boston)

17:00 ANAPLASTIC LARGE CELL LYMPHOMA – A MATURE T CELL MALIGNANCY WITH AN IMMATURE T CELL ORIGIN

S. Turner (Cambridge)

17:15 Discussion

EU2022.CZ

This programme will take place under the auspices of the Government of the CR on the occasion of Czech Presidency in the EU Council.



J. BAKEŠ HALL / FRIDAY 14th OCTOBER 2022

INTERNATIONAL BRNO ONCOLOGY DAY

8:50–10:20 IBOD BREAKING NEWS IN ONCOLOGY 2022 – CURRENT TREATMENT STANDARD

Chairs: F. Lordick, G. Prager, M. Palácová,
D. Ribnikar (Leipzig, Vienna, Brno, Ljubljana)

8:50 EARLY BREAST CANCER

M. Palácová (Brno)

9:05 METASTATIC BREAST CANCER

D. Ribnikar (Ljubljana)

9:20 UPPER GI TUMOURS

F. Lordick (Leipzig)

9:35 COLORECTAL AND PANCREATIC CANCER

G. Prager (Wien)

9:50 LUNG CANCER

S. Peters (Lausanne)

10:05 Discussion

10:15 Break

10:30–12:00 IBOD GENITOURINARY TRACT TUMORS

Chairs: T. Büchler, A. Poprach, M. Schmidinger,
P. Hammerer (Praha, Brno, Vienna, Braunschweig)

10:30 MOLECULAR SUBTYPING OF UROTHELIAL CANCER – POTENTIAL CLINICAL IMPLICATIONS

A. Poprach, P. Fabián, M. Staník, R. Lakomý (Brno)

10:45 TREATMENT OF RECURRENT AND REFRACTORY TESTICULAR TUMORS

N. Mego (Bratislava)

11:00 HIGH-DOSE TESTOSTERON TREATMENT FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

T. Büchler (Praha)

11:15 ADJUVANT THERAPY IN RENAL CELL CARCINOMA

B. Melichar (Olomouc)

11:30 EMERGING THERAPIES FOR RENAL CELL CANCER

M. Schmidinger (Vienna)

11:45 GQL WITH ARTA – IMPLICATIONS FOR TREATMENT SELECTION

P. Hammerer (Braunschweig)

12:00 Lunch

13:00–14:30 IBOD MEET THE EXPERTS (Young Oncologists Program)

Chairs: F. Lordick, D. Ribnikar, N. Mego, I. Kiss (Leipzig, Ljubljana, Bratislava, Brno)

13:00 74-YEAR OLD WOMAN WITH LOCALLY ADVANCED GASTRIC CANCER AND HIGH MICROSATELLITE INSTABILITY – A CASE REPORT

L. Thierfelder (Leipzig)

13:15 PANCREATIC CANCER – MULTIMODAL APPROACH FOR LONG-TERM SURVIVAL

D. Dufek (Brno)

13:30 CHEMOTHERAPY RESISTANCE IN TESTICULAR GERM CELL TUMOR – A CASE REPORT

Z. Országhová (Bratislava)

13:45 DE NOVO METASTATIC HR+/HER2– INVASIVE LOBULAR CARCINOMA (ILC) OF THE BREAST – A CLINICAL CASE

D. Stefanovski (Ljubljana)

14:00 A YOUNG PATIENT WITH MSI-H RECTAL CARCINOMA – IMMUNOTHERAPY AND ITS ROLE IN TREATMENT

T. Sokop, R. Obermannová (Brno)

14:15 Discussion

14:30 Break

14:45–15:45 IBOD ADVANCES IN CANCER BIOLOGY

Chairs: P. Müller, S. Bořilová, B. Kobitzsch (Brno, Leipzig)

14:45 CLINICAL APPLICATION OF LIQUID BIOPSY

S. Bořilová (Brno)

14:55 ERA1 – PREDICTIVE ROLE OF DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING IN EARLY RESPONSE EVALUATION OF ESOPHAGO-GASTRIC JUNCTION CANCER DURING NEOADJUVANT STANDARD CHEMOTHERAPY

B. Kobitzsch (Leipzig)

- 15:05 **BIOLOGICAL DOSE ASSESSMENT OF TWO TYPES OF TELETHERAPY AND TWO TYPES OF BRACHYTHERAPY**
Z. Kocsis, P. Ágoston, G. Farkas, G. Sándor, G. Székely, J. Kliton, L. Gesztesi, T. Major, C. Pesznyák, A. Herein, G. Stelczer, C. Polgár, Z. Jurányi (Budapest)
- 15:15 **IDENTIFICATION OF GENE EXPRESSION PATTERNS ASSOCIATED WITH EPITHELIAL-MESENCHYMAL TRANSITION IN LUNG CANCER CELLULAR MODEL**
A. Martišová, L. Sommerová, I. Selingerová, A. Krejčí, T. Kolářová, F. Zavadil Kokáš, R. Hrstka (Brno)
- 15:25 **MASS SPECTROMETRY ANALYSIS OF EXTRACELLULAR VESICLES FROM MALIGNANT ASCITES HIGHLIGHTS THE ROLE OF TUMOR MICROENVIRONMENT IN PROGRESSION OF OVARIAN CANCER**
V. Hlaváčková Pospíchalová, A. Vyhliđalová Kotrbová, K. Gömöryová, D. Potěšil, M. Bednaříková, J. Hausnerová, L. Minář, V. Weinberger, I. Crha, V. Bryja (Brno)
- 15:35 Discussion



R. WERNER HALL / 14th OCTOBER 2022

8:50-10:20	PATIENT-CENTRED CANCER CARE AND SURVIVORSHIP I Chairs: J. Loonen, T. Kepák (Nijmegen, Brno)	10:45	RIGHT TO BE FORGOTTEN FOR CANCER SURVIVORS – EU EXPERIENCES AND OBJECTIVES F. Meunier (Brussels)
8:50	PERSON CENTERED CARE IN CANCER SURVIVORSHIP CARE J. Loonen (Nijmegen)	11:00	PRÁVNÍ ASPEKTY EKONOMICKO-SOCIÁLNÍCH PODMÍNEK CHRONICKY NEMOCNÝCH PACIENTŮ A. Tobiášová (Brno)
9:10	VÝZNAM HEREDITÁRNÍ PREDISPOZICE U CHILDHOOD CANCER SURVIVORS V. Bajčiová, K. Drábová (Brno)	12:00	Oběd
9:20	SEKUNDÁRNÍ NÁDORY U PACIENTŮ PO ONKOLOGICKÉ LÉČBĚ V DĚTSTVÍ J. Kruseová, A. Zichová, A. Lukš, B. Malinová, T. Eckschlager (Praha)	13:00-15:00	PATIENT-CENTRED CANCER CARE AND SURVIVORSHIP III Chairs: M. Svoboda, D. Ondruš (Brno, Bratislava)
9:30	DLOUHODOBÉ SLEDOVÁNÍ PACIENTŮ PO ALOGENNÍ TRANSPLANTACI KRVETVORNÝCH BUNĚK V DĚTSKÉM VĚKU P. Keslová (Praha)	13:00	SHARED-DECISION MAKING PROCESS AND ITS IMPLEMENTATION IN DAILY PRACTICE – EXPERIENCE FROM DENMARK K. Dahl Steffensen (Vejele)
9:40	POZDNÍ NÁSLEDKY LÉČBY A ADRESNÁ PÉČE O VYLÉČENÉ DĚTSKÉ ONKOLOGICKÉ PACIENTY T. Kepák, H. Hrstková, V. Bajčiová, T. Sovová, V. Dušek, M. Holíková, L. Štrublová, K. Kepáková (Brno)	13:30	TESTICULAR CANCER LONG-TERM FOLLOW-UP AND OTHER PRIMARY UROLOGIC MALIGNANCIES D. Ondruš (Bratislava)
9:50	SPEKTRUM PSYCHOSOCIÁLNÍCH NESNÁZÍ PACIENTŮ CENTRA PRO NÁSLEDNOU PÉČI – FORMOVÁNÍ SPOLUPRÁCE TÝMU A VYPLÝVAJÍCÍ ÚLOHA PSYCHOLOGA J. Kozák (Žďárec)	13:45	XEROSTOMIE PO ONKOLOGICKÉ LÉČBĚ A MOŽNOSTI JEJÍHO OVLIVNĚNÍ P. Urbánková (Brno)
10:00	VYTVOŘENÍ A OVĚŘENÍ PILOTNÍHO PROGRAMU PRO SLEDOVÁNÍ POZDNÍCH NÁSLEDKŮ LÉČBY V OBLASTI POHYBOVÉHO CHOVÁNÍ A SPÁNKU NA DISPENZÁRNÍ ONKOLOGICKÉ AMBULANCI T. Vyhlídal, J. Dygrýn, T. Kepák, V. Bajčiová, F. Chmelík (Olomouc, Brno)	14:00	SPÁNEK A SPÁNKOVÝ ŠTRES – JAK NESTÁT SPÁNKU V CESTĚ, I KDYŽ SE SVĚT OTRÁSL V ZÁKLADECH M. Světlák (Brno)
10:10	Discussion	14:15	PORUCHY SPÁNKU U ONKOLOGICKÉHO PACIENTA – DIAGNOSTIKA A LÉČBA P. Turčáni (Brno)
10:20	Break	14:30	SEXUOLOGICKO-ANDROLOGICKÉ DŮSLEDKY ONKOLOGICKÉ LÉČBY T. Šrámková (Brno)
10:30-12:00	PATIENT-CENTRED CANCER CARE AND SURVIVORSHIP II Chairs: M. Svoboda, A. Tobiášová, J. Kopsa Těšinová (Brno, Praha)	14:45	Discussion
10:30	SURVIVORSHIP – WHAT THE CANCER SURVIVORS REALLY EXPECT F. De Lorenzo (Roma)		



EU2022.CZ

This programme will take place under the auspices of the Government of the CR on the occasion of Czech Presidency in the EU Council.



Prof. Carmelo Rizzari

University of Milano-Bicocca, Italy

PRECISION MEDICINE IN PEDIATRIC ONCOLOGY

Thursday 13.10.2022, 2:15 p.m., R. Werner Hall

Carmelo Rizzari is a Professor of Paediatrics at the University of Milano-Bicocca, Italy and has been involved in the field of paediatric leukaemias with a special interest in both traditional and innovative chemotherapy agents. He is currently running the Paediatric Haematology-Oncology Unit in Monza (MBBM Foundation, ASST Monza, University of Milano-Bicocca, Italy), which is one of the largest centres for the diagnosis and treatment of haematological malignancies in Italy.

Since the start of his career, he has been involved in the field of paediatric leukaemias with a special interest in both traditional and innovative chemotherapy agents.

He is currently Chairman of the AIEOP (Associazione Italiana di Ematologia ed Oncologia Pediatrica) Acute Lymphoblastic Leukaemia (ALL) Committee which aims to improve the knowledge and treatment of childhood ALL in the country. He is also a member of the national AIEOP scientific committees for first-line and relapsed trials for ALL and AML and an active member of several scientific and steering international committees (e.g. AIEOP-BFM ALL trials, International BFM Study Group, ITCC, INTREALL). Within the ITCC Consortium (Innovative Therapies for Children with Cancer), he served as a member of the Quality and Accreditation Committee and is currently the Chair of the ITCC Centre of Monza, Italy.

For several years now, he is also serving as the representative of the International BFM Study Group at ENPREMA (European Network for Paediatric Research at EMA) which aims to foster and integrate at the European level the research and innovation in different paediatric areas.

He is also currently national PI or Co-PI or local site PI for several national or international phase I and II Pharma sponsored or Academia driven studies involving innovative drugs for resistant/relapsed leukaemias and lymphomas.

Author or co-author of over 150 peer-reviewed scientific publications, he has also actively participated as an invited speaker in several

international scientific meetings and disease-specific working groups.

As of January 2022, he is President of the European Society for Paediatric Oncology (SIOP Europe, or SIOPE). He previously served as Co-Chair of the SIOP Europe Clinical Research Council, which gathers the thirty-five National Paediatric Haematology-Oncology Societies and the nineteen European Clinical Trial Groups.

Selected recent papers:

1. Khalil A, Würthwein G, Golitsch J ... Rizzari C et al. Pre-existing antibodies against polyethylene glycol reduce asparaginase activities on first administration of pegylated E. coli asparaginase in children with acute lymphocytic leukemia. *Haematologica*. 2022; 107(1): 49–57.
2. Locatelli F, Zugmaier G, Rizzari C et al. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. *JAMA*. 2021; 325(9): 843–854.
3. Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. *N Engl J Med*. 2020; 382(19): 1811–1822.

On the occasion of Brno Oncology Days, Prof. Rizzari will open the educational session Precision Medicine in Pediatric Oncology.



Michael Craig Cox, Pharm.D., MHS, BCOP

Vice President, Clinical Development, Day One Biopharmaceuticals, San Francisco, USA

GENE FUSION PROTEINS AS THERAPEUTIC TARGETS IN PEDIATRIC ONCOLOGY

Thursday 13.10.2022, 2:55 p.m., R. Werner Hall

Dr. Cox currently serves as Vice President, Clinical Development at Day One Biopharmaceuticals where he leads pediatric clinical development of DAY101.

Over his career, he has led the clinical development, product launches and life cycle management of numerous oncology products including splenectinib (Retvmo™), larotrectinib (VITRAKVI®), radium-223 (Xofigo®), regorafenib (Stivarga®), sorafenib (Nexavar®) cetuximab (ERBITUX®), denosumab (XGEVA®) and darbepoetin alfa (Aranesp®).

Prior to joining Day One, Dr Cox served as Executive Director, Pediatric Clinical Development at Loxo Oncology where he led medical affairs and pediatric clinical development. Prior to Loxo Oncology, he held global and regional medical affairs positions of increasing responsibility at Bayer Consumer Care AG, Basel, Switzerland, Merck KGaA, Darmstadt, Germany and Amgen, Inc., Thousand Oaks, California.

Dr. Cox received his Pharm.D. from Ohio Northern University and an MHS in Clinical Research from Duke University's School of Medicine. Dr. Cox completed pharmacy practice residencies at Mission Hospitals in Asheville, North Carolina and the University of Pittsburgh Cancer Institute – University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. He completed a medical oncology/clinical drug development fellowship in the Clinical Pharmacology Section, Center for Cancer Research at the National Cancer Institute, Bethesda, Maryland.

Dr. Cox has published abstracts and manuscripts in journals including The New England Journal of Medicine, Lancet Oncology, the Journal of Clinical Oncology, Cancer and Clinical Cancer Research. He is a member of numerous cancer research organizations including the American Association of Cancer Research, the American Society of Clinical Oncology, and the European Society of Medical Oncology. Dr. Cox is a Board Certified Oncology Pharmacist.

Selected recent papers:

1. Kilburn LB, Jabado N, Franson A, Chi SN, Fisher MJ, Hargrave DR, Hansford JR, Ziegler DS, Landi D, Kang, HJ, Gerber, NU, Yalon-Oren, M, Cornelio I, Blackman SC, Cox MC, Witt O, Prados M, Mueller S. FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma. *J Clin Oncol* 2021; 39(15): TPS10056.

2. Gerdemann U, Lee YA, Henry D, Smith S, Ortiz MV, Rothenberg SM, Raju SG, Cox MC, Bender JLG, Pappo AS, Frazier AL, Kang HJ. First experience of LOXO-292 in the management of pediatric patients with RET-altered cancers. *J Clin Oncol* 2019; 37(15): 10045.

3. Kummar S, Mascarenhas L, Geoerger B, Turpin B, Cox MC, Yu S, Nanda S, Hiemeyer F, Keating KN, Chirila C, Gnanasakthy A, Davenport E, Hong DS, Drlon AE. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. *J Clin Oncol* 2019; 37(15): 6602.

On the occasion of Brno Oncology Days, Dr. Cox will deliver an invited lecture on the topic "Gene fusion proteins as therapeutic targets in pediatric oncology".



Stefaan Van Gool, MD, PhD.

Immuno-Oncological Centre Cologne, Germany

ANTICANCER VACCINES IN PEDIATRIC ONCOLOGY

Thursday 13.10.2022, 3:10 p.m., R. Werner Hall

Stefaan Van Gool, MD, PhD, is medical director of the Praxis für Immunonkologie und Translationale Medizin. Within the the GMP laboratory of the Immun-onkologisches Zentrum Köln (www.IOZK.de) he also has the function of Qualified Person and Responsible Medical Person for the release of the produced dendritic cell vaccines (IO-Vac®). IO-Vac® is an approved Advanced Therapy Medicinal Product since 27 may 2015.

Before his arrival in IOZK in August 2015, Stefaan Van Gool was full Professor and Clinical Head for Pediatric Neuro-Oncology at the University of Leuven in Belgium. There, he pioneered the dendritic cell vaccination as treatment strategy for patients with Glioblastoma Multiforme, and treated the first patient within Europe in 2001. The consecutive clinical trials were accompanied with preclinical in vitro and in vivo studies to explore the mechanisms and support the strategy of dendritic cell vaccination for this disease entity.

At the IOZK, he expanded this form of active specific immunotherapy with short and long peptide vaccines. He introduced the concept of immunogenic cell death immunotherapy (using oncolytic viruses like Newcastle Disease Virus, and modulated electrohyperthermia technology). He implemented passive immunotherapy and adoptive T cell immunotherapy. Finally, he elaborated several strategies for modulatory immunotherapy.

By working out all these different modes of immunotherapy, the individualized multimodal immunotherapy was created as an innovative treatment concept to treat solid tumors and brain tumors, which is implemented in connection to the standard of care. Real World Data from his Praxis are regularly reported in the peer-reviewed literature.

Selected recent papers:

1. Wolff JE, Van Gool SW, Kutluk T, Diez B, Kebudi R, Timmermann B, Garami M, Sterba J, Fuller GN, Bison B, Kordes UR. Final results of the choroid plexustumrostudy CPT-SIOP-2000. *J Neurooncol* 2022; 156: 599–613.

2. Van Gool SW, Makalowski J, Bitar M, Van de Vliet P, Schirrmacher V, Stuecker W. Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients. *Genes & Immunity* 2022, <https://doi.org/10.1038/s41435-022-00162-y>.

3. Khodayari H, Khodayri S, Ebrahimi E, Hadjilooei F, Vesovic M, Mahmoodzadeh H, Saric T, Stücker W, Van Gool SW, Hescheler J, Nayernia K. Stem cells-derived natural killer cells for cancer immunotherapy: current protocols, feasibility, and benefits of ex vivo generated natural killer cells in treatment of advanced solid tumors. *Cancer Immunol Immunother* 2021; PMID 34218295.

4. Elens I, Deprez S, Billiet T, Sleurs C, Labarque V, Uyttebroeck A, Van Gool SW, Lemier J, D’Hooge R. Methylene tetrahydrofolate reductase A1298C polymorphisms influence the adult sequelae of chemotherapy in childhood- leukemia survivors. *PLoS One* 2021; 16: e0250228.

On the occasion of Brno Oncology Days, Dr. Van Gool will deliver an invited lecture on the topic “Anticancer vaccines in pediatric oncology”.



Prof. Nicolas André

Aix Marseille University, France

LIQUID BIOPSIES IN EXTRA-CRANIAL SOLID TUMORS AS AN INTEGRAL PART OF PRECISION ONCOLOGY
Thursday 13.10.2022, 4:30 p.m., R. Werner Hall

Prof. Nicolas André is Professor in Pediatric Oncology in the Department of Hematology & Pediatric Oncology in the “Hôpital pour Enfants de La Timone”, AP-HM and head of the SMARTC CRCM (Centre de Recherche en Cancérologie de Marseille), Aix Marseille University, France. He is also the deputy Vice President for Health at the Aix Marseille University and Vice president for Research at AP-HM. He gained his MD in 2002 and a PhD in 2003. He is the former president of the “Société Francophone de Recherche en Pédiatrie”.

Currently, his research interests and topics include paediatric brain tumors, pediatric rare tumors and pharmacology (new anticancer agents, metronomic chemotherapy). He has developed over the years an international expertise in metronomic chemotherapy.

He is the author of over 200 peer reviewed publications and book chapters and has given lectures worldwide.

Selected recent papers:

1. Cahn F, Revon-Riviere G, Min V, Rome A, Filaine P, Pelletier A, Abed S, Gentet JC, Verschuur A, André N. Blood-Derived Liquid Biopsies Using Foundation One (R) Liquid CDx for Children and Adolescents with High-Risk Malignancies: A Monocentric Experience. *Cancer* 2022; 14(11): 2774.

2. Berlanga P, Pierron G, Lacroix L, Chicard, M, de Beaumais TA, Marchais A, Harttrampf AC, Iddir Y, Larive A, Fernandez AS, Hezam I, Chevassus C, Bernard V, Cotteret S, Scoazec JY, Gauthier A, Abbou S, Corradini N, André N, Aerts I, Thebaud E, Casanova M, Owens C, Hladun-Alvaro R, Michiels S, Delattre O, Vassal G, Schleiermacher G, Geoerger B. The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies. *Cancer Discover* 2022; 12(5): 1266–1281.

3. Gouton E, Malissen N, André N, Jeanson A, Pelletier A, Testot-Ferry A, Gaudy-Marqueste, C, Dahan L, Tabouret E, Chevalier T, Greillier L, Tomasini P. Clinical Impact of High Throughput Sequencing on Liquid Biopsy in Advanced Solid Cancer. *Current Oncol* 2022; 29(3): 1902–1918.

4. Bautista F, Paoletti X, Rubino J, Brard C, Rezai K, Nebchi S, André N, Aerts I, De Carli E, van Eijkelenburg N, Thebaud E, Corradini N, Defachelles AS, Ducassou S, Morscher RJ, Vassal G, Geoerger B. Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSe-ESMART Trial. *J Clin Oncol* 2021; 39(32): 3546.

5. Morscher RJ, Brard C, Berlanga P, Marshall LV, André N, Rubino J, Aerts I, De Carli E, Corradini N, Nebchi S, Paoletti X, Mortimer P, Lacroix L, Pierron G, Schleiermacher G, Vassal G, Geoerger B. First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSe-ESMART trial. *Eur J Cancer* 2021; 157: 268–277.

On the occasion of Brno Oncology Days, Prof. André will deliver an invited lecture on the topic “Liquid biopsies in extra-cranial solid tumors as an integral part of precision oncology”.



Prof. Suzanne Turner, PhD

University of Cambridge, Great Britain

ANAPLASTIC LARGE CELL LYMPHOMA – A MATURE T CELL MALIGNANCY WITH AN IMMATURE T CELL ORIGIN
Thursday 13.10.2022, 5:00 p.m., R. Werner Hall

Suzanne obtained her PhD from the world-renowned Paterson Institute for Cancer Research and the Christie Hospital in Manchester where she examined the potential toxic side-effects of chemoprotective gene therapy. This work was a collaborative effort with what was at that time the AstraZeneca Central Toxicology Labs at Alderley Edge. Following this training period Suzanne moved to a research post at the Babraham Institute in Cambridge where she began to investigate mechanisms of Lymphomagenesis, a subject that she has pursued to become a world-expert in paediatric lymphomas, specifically Anaplastic Large Cell Lymphoma. For the past 16 years Suzanne has been leading an academic research group at the University of Cambridge within the Department of Pathology and based at the Addenbrooke's Hospital campus in Cambridge. It is here that Suzanne conducts academic research of an international standard. Suzanne is also the director of postgraduate education in the Department of Pathology.

In 2007, Suzanne was awarded the prestigious Leukaemia and Lymphoma Research Bennett Fellowship and in 2012 a further 5-year senior lectureship award. Amongst her achievements are the inception and establishment of the European Research Initiative on ALCL, a study group that brings together scientists from across Europe to foster collaboration and advancement in this important area of health research. Suzanne was also the lead of 'ALKATRAS', a European Union Marie Curie Innovative Training Network of 14 research groups in 7 EU countries and is currently non-clinical chair of the European Inter-Group for Collaboration into Childhood Non-Hodgkin Lymphoma, co-chair of the Cancer Research UK Cambridge Centre Paediatric Programme and biological lead for the National Cancer Research Institute paediatric lymphoma Clinical Study Group. Suzanne collaborates with a wide array of scientists and labs around the world, most notably the Uganda Cancer Institute in Kampala with whom she is work-

ing towards finding better therapies for children with cancer. Amongst her other interests Suzanne is the scientific advisor to the Alex Hulme Foundation and Francesca Richardson Trust. She is also a member of both the American and British Associations for Cancer, the Children's Cancer and Leukaemia Group in the UK and the International Society for Paediatric Oncology. Suzanne also sits on the scientific committee of the European arm of SIOP, the MHRA plastics, reconstructive and aesthetic surgery committee and the European Commission's Scientific committee on Health, Environmental and Emerging Risks working group on breast implants and cancer. In addition, she is a member of the review panels of the World Cancer Research Fund and the Swedish Research Council's medicine and health review panel.

Selected recent papers:

1. Karaca Atabay E, Mecca C, Wang Q ... Turner SD et al. Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. *Blood* 2022; 139(5): 717-731.
2. Newman AM, Zaka M, Zhou PX ... Turner SE et al. Genomic abnormalities of TP53 define distinct risk groups of paediatric B-cell non-Hodgkin lymphoma. *Leukemia* 2022; 36(3): 781-789.
3. Garland GD, Ducray SP, Jahangiri L, Pucci P, Amos Burke GA, Monahan J, Lai R, Merkel O, Schiefer AI, Kenner L, Bannister AJ, Turner SD. BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL. *Cancers (Basel)* 2021; 14(1): 151.

On the occasion of Brno Oncology Days, Prof. Turner will deliver an invited lecture on the topic „Anaplastic large cell lymphoma – a mature T cell malignancy with an immature T cell origin“.



Domen Ribnikar, MD

Institute of Oncology Ljubljana, Slovenia

CURRENT TREATMENT STANDARD FOR METASTATIC BREAST CANCER

Friday, 14.10.2022, 9:05 a.m., J. Bakeš Hall

I graduated from Medical Faculty of Ljubljana in June of 2008 and in August 2008 I started my internship at General Hospital Jesenice, which was concluded with professional examination in February 2009. In the same month I started working at the Institute of Oncology Ljubljana in Medical Oncology Department and within the same year I started my residency of Medical Oncology. In 2014 I did my fellowship at the Champalimaud Cancer Center in Lisbon, Portugal, under the supervision of dr Fatima Cardoso.

I finished my residency in May 2015 and I started working as a staff specialist with breast cancer and genitourinary cancer patients at the Institute of Oncology Ljubljana. In September 2016 I left Slovenia and moved to Toronto, Canada, for a 2-year breast cancer clinical research fellowship. My main mentor at the Princess Margaret Cancer Center was doctor Eitan Amir, who is also an assistant professor at the University of Toronto. I have been actively collaborating with breast cancer experts from Toronto and Lisbon and we have published many original research articles on pubmed. I also received many different awards for poster presentations during many international congresses, mainly in Europe, but also worldwide. In September 2017 I received the Best Poster award for original research entitled Reporting of randomized trials in common cancers in the lay media.

I am very proud and grateful for having these opportunities to go abroad and to learn from breast cancer experts worldwide to share new findings with my younger colleagues and to do my best for my patients. I am also very grateful that my Mum, who is a breast cancer survivor, is doing well after many years after her diagnosis and last but not the least, I do thank to my own family (my wife Nina and our two daughters Julija and Lana Mae) for all support and giving me further strength during all these years.

Selected recent papers:

1. Ratosa I, Dobnikar N, Bottosso M, Dieci MV, Jacot W, Poudroux S, Ribnikar D, Sinoquet L, Guarneri V, Znidaric T, Darlix A, Griguelo G. Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: Real-world data from a multicentric European cohort. *Int J Can* 2022; 151(8): 1355–1366.

2. Blatnik A, Ribnikar D, Dragos VS, Novakovic S, Stegel V, Kuzmanov BG, Boc, N, Peric B, Skerl P, Klancar G, Krajc M. BAP1-deficient breast cancer in a patient with BAP1 cancer syndrome. *Breast Cancer* 2022; 29(5): 921–927.

3. Veitch Z, Ribnikar D, Tilley D, Tang PTA, King K, Bedard PL, Lupichuk S, Cescon DW. No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. *Br J Cancer* 2022; 126(6): 881–888.

4. Lohmann AE, Soldera SV, Pimentel I, Ribnikar D, Ennis M, Amir E, Goodwin PJ. Association of Obesity With Breast Cancer Outcome in Relation to Cancer Subtypes: A Meta-Analysis. *J Natl Cancer Inst* 2021; 113(11): 1465–1475.

On the occasion of Brno Oncology Days, Dr. Ribnikar will deliver an invited lecture on the topic “Current treatment standard for metastatic breast cancer”.



Prof. Florian Lordick, MD, PhD.

Professor of Medicine, University of Leipzig, Germany

CURRENT TREATMENT STANDARD FOR UPPER GI TUMOURS

Friday, 14.10.2022, 9:20 a.m., J. Bakeš Hall

Dr. Lordick is a Full Professor of Medicine at the University of Leipzig, Germany. He was appointed as director of the University Cancer Center Leipzig in 2012. Since 2020, he also chairs the Department of Medicine II (oncology, gastroenterology, hepatology, pulmonology, and infectious diseases) at the Leipzig Medical Center.

He is the past-chairman of the EORTC GI Tract Cancer Working Group and since 2020 he is director of education of the European Society for Medical Oncology (ESMO). He is also the current president of the International Gastric Cancer Association (IGCA). Dr. Lordick's scientific focus is on clinical and translational research in gastrointestinal tract cancers. His research is funded by the German Cancer Aid, the German Ministry of Education and Research and by the European Commission.

Dr. Lordick has authored and co-authored more than 400 peer-reviewed articles. He is deputy-editor-in-chief of the *Journal of Cancer Research and Clinical Oncology* (Springer), the official scientific organ of the German Cancer Society. He also is associate editor of *Gastric Cancer* (Springer) and of *ESMO Open* (Elsevier) as well as an editorial board member of *Annals of Oncology* (Elsevier).

Selected recent papers:

1. Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Pieszen G, Vogel A, Smyth EC; ESMO Guidelines Committee. Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2022; S0923-7534(22)01851-8.

2. Obermannová R, Alsina M, Cervantes A, Leong T, Lordick F, Nilsson M, van Grieken NCT, Vogel A, Smyth EC; ESMO Guidelines Committee. Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Ann Oncol* 2022; S0923-7534(22)01850-6.

3. Hacker UT, Hasenclever D, Baber R, Linder N, Busse H, Obermannová R, Zdrzilova-Dubská L, Valik D, Lordick F. Modified Glasgow prognostic score (mGPS) is correlated with sarcopenia and dominates the prognostic role of baseline body composition parameters in advanced gastric and esophagogastric junction cancer patients undergoing first-line treatment from the phase III EXPAND trial. *Ann Oncol* 2022; 33(7): 685–692.

4. Lordick F, Obermannová R, Smyth EC. Targeting HER2 for localised oesophageal cancer. *Lancet Oncol* 2022; 23(2): 188–190.

5. Lordick F, Al-Batran SE, Ganguli A, Morlock R, Sahin U, Türeci Ö. Patient-reported outcomes from the phase II FAST trial of zolbetuximab plus EOX compared to EOX alone as first-line treatment of patients with metastatic CLDN18.2+gastroesophageal adenocarcinoma. *Gastric Cancer* 2021; 24(3): 721–730.

6. Haffner I, Schierle K, Raimúndez E, Geier B, Maier D, Hasenauer J, Luber B, Walch A, Kolbe K, Riera Knorrenschild J, Kretzschmar A, Rau B, Fischer von Weikersthal L, Ahlborn M, Siegler G, Fuxius S, Decker T, Wittekind C, Lordick F. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: Results From the Prospective Multicenter VARIANZ Study. *J Clin Oncol* 2021; 39(13): 1468–1478.

On the occasion of Brno Oncology Days, Prof. Lordick will deliver an invited lecture on the topic "Current treatment standard for upper GI tumours".



Assoc. Prof. Gerald Prager, MD

Comprehensive Cancer Center Vienna, Austria

CURRENT TREATMENT STANDARD FOR COLORECTAL AND PANCREATIC CANCER

Friday, 14.10.2022, 9:35 a.m., J. Bakeš Hall

Dr. Gerald Prager is an Associate Professor of Medicine Board Certified for Internal Medicine and Board Certified for Hematology and Medical Oncology. After he graduated from the Medical School of the University of Vienna (MUV, Austria), he completed postdoctoral training at the University of California, San Diego (UCSD, USA). He was a Visiting Professor at the Norris Cancer Center, University of Southern California (USC) in Los Angeles (USA) in 2011.

In 2012 Dr. Prager became an Associate Professor at the Medical University of Vienna. Currently, Dr. Prager is Director of the Gastrointestinal Cancer Program of the Department of Medical Oncology at the Medical University of Vienna and Comprehensive Cancer Center Vienna. Furthermore, he leads the Unit for Precision Medicine in Cancer.

The main research interest of Dr. Prager's lab is on (tumor-) angiogenesis via regulation of cell survival and migration by cell/extracellular-matrix interaction. His work is honored by 20 international awards and has resulted in publications in international highly renowned journals. Dr. Prager is a member of the Scientific Committee of the European Society of Medical Oncology (ESMO).

Selected recent papers:

1. Bianconi D, Fabian E, Herac M, Kieler M, Thaler J, Prager G, Unseld M. Expression of CD98hc in Pancreatic Cancer and Its Role in Cancer Cell Behavior. *J Cancer* 2022; 13(7): 2271-2280.
2. Prager G, Köhne CH, O'Connor JM, Rivera F, Santini D, Wasan H, Phelip JM. The Screening and COnsensus Based on Practices and Evidence (SCOPE) Program-Results of a Survey on Daily Practice Patterns for Patients with mCRC. *Curr Oncol* 2021; 28(3): 2097-2106.

3. Carrato A, Melisi D, Prager G, Westphalen CB, Ferreras A, D'Esquermes N, Taieb J, Mercadé TM. Chart review of diagnostic methods, baseline characteristics and symptoms for European patients with pancreatic cancer. *Future Oncol* 2021; 17(15): 1843-1854.

4. Taberero J, Taieb J, Prager GW, Ciardiello F, Fakih M, Leger C, Fougeray R, Amellal N, van Cutsem E. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. *Future Oncol* 2021; 17(16): 1977-1985.

5. Prager GW, Oehler L, Gerger A, Mlineritsch B, Andel J, Petzer A, Wilthoner K, Sliwa T, Pichler P, Winder T, Heibl S, Gruenberger B, Laengle F, Hubmann E, Korger M, Pecherstorfer M, Djanani A, Neumann HJ, Philipp-Abbrederis K, Wöll E, Trondl R, Arnold-Schrauf C, Eisterer W. Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study. *Eur J Cancer* 2021; 143: 101-112.

6. Taghizadeh H, Mader RM, Müllauer L, Erhart F, Kautzky-Willer A, Prager GW. Precision Medicine for the Management of Therapy Refractory Colorectal Cancer. *J Pers Med* 2020; 10(4): 272.

On the occasion of Brno Oncology Days, Assoc. Prof. Prager will deliver an invited lecture on the topic "Current treatment standard for colorectal and pancreatic cancer".



Prof. Michal Mego, MD, DSc.

National Cancer Institute, Bratislava, Slovakia

TREATMENT OF RECURRENT AND REFRACTORY TESTICULAR TUMORS

Friday, 14.10.2022, 10:45 a.m., J. Bakeš Hall

He has been a Professor of oncology and Head of the 2nd Oncology Department, Faculty of Medicine, Comenius University and the National Cancer Institute (NOU) since 2017. He has been a head of Translational Research Unit, LF UK and NOU since 2010. From 2007 to 2011, he worked as an Assistant Professor at the 2nd Oncology Clinic of LFUK and NOU and as a Research Assistant at the Institute of Experimental Oncology, Slovak Academy of Sciences. His main research areas are testicular germ cell tumors, circulating tumor cells and probiotics.

In 2020 he received DSc (Doctor of Science) for his thesis "Clinical and biological value of circulating tumor cells in breast cancer". In 2014, he was a Visiting Associate Professor and in 2008–2009 visiting Research Scholar at the University of Texas, MD Anderson Cancer Center, Houston. He studied at the Vienna School of Clinical Research and the Vienna Medical University from 2004 till 2007. He graduated at the VSCR and obtained a Diploma in Clinical Research in 2007. In 2007, he completed an internship at the ESMO TRU visit in Vall d'Hebron, Barcelonan. He is a Doctor of Philosophy (PhD.) and his thesis "Possibilities of Application of Probiotics in Oncology" was the result of work at the Institute of Experimental Oncology, Slovak Academy of Sciences from 2001 to 2006. He has been board certified in Clinical Oncology at the Slovak Medical University in Bratislava in 2006. He has gained the ESMO Certificate in Clinical Oncology at the ESMO Conference in Paris in 2005. He attended the 8th FESC-AACR-ASCO Workshop in Switzerland in "Clinical Research Methods" in 2006. He graduated from the Faculty of Medicine, Comenius University in Bratislava in 2001.

For his work, he was awarded with: Ludovit Stur Order II class, Prize of the Minister of Education of Slovakia for Science and Technology (2019), Academic Award of the Head of Comenius University (2018), The Crystal Wing in the Category of Medicine and Science (2017), the Young Investigator Travel Grant Award

(9th International Symposium, Minimal Residual Cancer, 2013), Paris, Award of the Minister of Education of the Slovak Republic for Science and Technology 2011, AACR Translational Research Scholar-in-Training Award (2009), Best Poster Award, 7th International Symposium, Minimal Residual Cancer, Athens (2009), UICC ACSBI Award ACS / 08/006 (2008), ESMO Best Exam Award (2006). He is also the author of two patents of novel methods for detecting circulating tumor cells (CTC) in the blood.

Prof. Mego is a member of Editorial Board of Journals *Klinicka onkologie*, *Onkologia*, *BMC Cancer*, Guest Editor *Frontiers in Oncology* and *International Journal of Molecular Sciences*. Mego is a first author or co-author of more than 400 articles including more than 70 peer-reviewed articles.

Selected recent papers:

1. Palacka P, Janega P, Polakova H, Slopovsky J, De Angelis V, Mego M. Pericardial malignant infiltration as the cause of sudden death of a patient with metastatic urothelial carcinoma treated with atezolizumab. *BMC Urol* 2022; 22(1): 108.
2. Hires M, Jane E, Kalavska K, Chovanec M, Mego M, Kasak P, Bertok T, Tkac J. Glycan signatures for the identification of cisplatin-resistant testicular cancer cell lines: Specific glycoprofiling of human chorionic gonadotropin (hCG). *Cancer Med* 2022; 11(4): 968–982.
3. Kalavska K, Sestakova Z, Mlcakova A ... Mego M. Are Changes in the Percentage of Specific Leukocyte Subpopulations Associated with Endogenous DNA Damage Levels in Testicular Cancer Patients? *Int J Mol Sci* 2021; 22(15): 8281.

On the occasion of Brno Oncology Days, Prof. Mego will deliver an invited lecture on the topic "Treatment of recurrent and refractory testicular tumors".



Assoc. Prof. Jacqueline Loonen

Radboud University Medical Center, Nijmegen, The Netherlands

PERSON CENTERED CARE IN CANCER SURVIVORSHIP CARE

Friday, 14.10.2022, 8:20 a.m., R. Werner Hall

Jacqueline Loonen is a pediatric oncologist with special expertise in stem cell transplantation and cancer survivorship care (CSC). Since 1. 5. 2014 she has been responsible for the CSC program in the Radboudumc. In 2017 she established the Radboudumc Center of Expertise for Cancer Survivorship, for long-term follow-up care for both adult and childhood cancer survivors. Currently, she is leading this Center of Expertise, where she is responsible for patient care, management, research and education.

Jacqueline Loonen developed and implemented an innovative care model for CSC: the “Personalized Cancer Survivorship Care model” (PCSC model), which comprises personalized follow-up care according to the principles of Person Centered Care. Within this model, risk based health surveillance is performed according to international guidelines. Management of late effects is done in collaboration with an extensive team of medical specialists and psychologists with expertise in the field of late effects. A multidisciplinary care infrastructure has been developed for the coordination of this comprehensive care. The model enables seamless transition of the survivors through the health care system.

In 2021 the Radboudumc Center of Expertise was rewarded with the golden certificate for Person Centered Care by Planetree International, a world-wide, non-profit organization for Person Centered Care.

Jacqueline Loonen is a member of the executive board of the Dutch Childhood Oncology Group for Late Effect Registration (DCCSS LATER) and is responsible for the nationwide ongoing study: The DCCSS LATER study.

As a member of the International Guideline Harmonization Group she participates in the development of international guidelines for long term follow up of childhood, adolescent and young adult cancer survivors.

Selected recent papers:

1. Stolze J, Teepen JC, Raber-Durlacher JE, Loonen J et al. Prevalence and Risk Factors for Hyposalivation and Xerostomia in Childhood Cancer Survivors Following Different Treatment Modalities-A Dutch Childhood Cancer Survivor Study Late Effects 2 Clinical Study (DCCSS LATER 2). *Cancer* 2022; 14(14): 3379.
2. Penson A, Walraven I, Bronkhorst E ... Loonen, J. The Impact of Cancer-Related Fatigue on HRQOL in Survivors of Childhood Cancer: A DCCSS LATER Study. *Cancer* 2022; 14(12): 2851.
3. van Kalsbeek RJ, Mulder RL, Haupt ... Loonen, JJ et al. The Pan-CareFollowUp Care Intervention: A European harmonised approach to person-centred guideline-based survivorship care after childhood, adolescent and young adult cancer. *Eur J Cancer* 2022; 162: 34–44.

On the occasion of Brno Oncology Days, Assoc. Prof. Loonen will deliver an invited lecture on the topic “Person centered care in cancer survivorship care”.



Françoise Meunier, MD, PhD, FRCP

European Academy of Cancer Sciences Science Policy Committee
Scientific Committee of the European Cancer Patients Coalition
Belgian Royal Academy of Medicine

RIGHT TO BE FORGOTTEN FOR CANCER SURVIVORS – EU EXPERIENCES AND OBJECTIVES

Friday, 14.10.2022, 10:45 a.m., R. Werner Hall

Françoise Meunier served as EORTC Director General (1991–2015) and oversaw the growth of the EORTC into a world-class cancer clinical research infrastructure. She remained active until November 9, 2018, as EORTC Director of Special Projects where she was a driving force behind a number of activities such as cancer survivorship initiatives.

She is a member of the Belgian Royal Academy of Medicine since 2006. In 2007, she was conferred the title of Baroness by His Majesty, The King Albert II of Belgium.

In 2009, she received the Pezcoller Foundation award as a recognition for her contribution to oncology.

She is a Fellow of the European Academy of Cancer Sciences. Since 2014, she is a board member of “Centre Scientifique de Monaco”. From 2015 until 2021, she was Vice-President of Federation of European Academies of Medicine and was a Board Member of the Alliance for Biomedical Research in Europe (2015–2018).

In 2015, she received the degree of Doctor of Medical Science (Honoris Causa) by the Queen’s University of Belfast, Northern Ireland, UK. From 2017 to December 2020, Prof. Meunier was a Member of the Scientific Panel for Health of the European Commission.

Prof. Meunier has been an active participant in cancer-related events throughout the past years, notably taking part in several summits of the European CanCer Organisation to discuss her cancer survivorship activities.

She is a member of the Scientific Committee of the European Cancer Patients Coalition. In 2020, her collaboration with ECPC, saw her project on the Right to be Forgotten for Cancer Survivors take a new dimension through its recognition within the Beating Cancer Plan and the Cancer Mission report. Since March 2021, Prof. Meunier is a member of the Steering Committee of Survivorship and Quality of life of ECO.

During several webinars on the Right to be Forgotten, Prof. Meunier renewed her calls for the formalisation of a European Cancer Survivorship Day, and the organisation of an annual event dedicated to cancer survivorship. She also expressed the need to develop a harmonised legal framework to deal with discrimination faced by former cancer patients, once declared cured by their oncologists. She also advocates for the creation of an implementation network to benefit from the expertise gathered by the 6 EU Member States who have already implemented the Right to be Forgotten.

On the occasion of Brno Oncology Days, Prof. Meunier will deliver an invited lecture on the topic “Right to be forgotten for cancer survivors – EU experiences and objectives”.



Prof. Karina Dahl Steffensen

Institute of Regional Health Research Faculty of Health Sciences University of Southern Denmark, Odense, Denmark

SHARED-DECISION MAKING PROCESS AND ITS IMPLEMENTATION IN DAILY PRACTICE – EXPERIENCE FROM DENMARK

Friday, 14.10.2022, 1:00 p.m., R. Werner Hall

Since 2014, MD Karina Dahl Steffensen has been CEO of Center for Shared Decision Making. She is one of the beacons within the area of Shared Decision Making, both nationally and internationally. Furthermore, she is the head of the Research Unit in Center for Shared Decision Making. Since 2018, she has been professor in clinical oncology at the Department of Regional Health Research at the University of Southern Denmark.

Karina has until recently been working as a consultant in the Department of Oncology with allocated working hours in the out-patient clinic, in which she applied shared decision making together with the patients. She is therefore highly experienced in applying shared decision making at both a practical and a theoretical level.

Her primary domain in Shared Decision Making is research within all clinical specialties within the field. Throughout her career, she has supervised 18 PhD projects and published more than 120 peer-reviewed scientific articles. In 2019, she was accepted in Kraks Blå Bog (Danish biographical dictionary) and she serves as a board member in Nordea-fonden and Titgenfonden. Additionally, she is head of the Scientific Board at Lillebaelt Hospital and member of the Danish Cancer Society's Scientific Board.

Selected recent papers:

1. von Essen HS, Stacey D, Steffensen KD, Guldager R, Poulsen FR, Piiil K. Decisional needs of patients with recurrent high-grade glioma and their families. *Neuro-Oncology Practice* 2022; 9(5): 402–410.

2. Witteman HO, Maki KG, Vaisson G, Finderup J, Lewis KB, Steffensen KD, Beaudoin C, Comeau S, Volk RJ. Systematic Development of Patient Decision Aids: An Update from the IPDAS Collaboration. *Medical Decision Making* 2021; 41(7): 736–754.

3. Kargo AS, Jensen PT, Lindemann K, Hjollund NHI, Lund B, Haae M, Moller S Hansen DG, Steffensen KD. The PROMova study comparing active and passive use of patient-reported outcome measures in ovarian cancer follow-up: effect on patient-perceived involvement, satisfaction with care, and usefulness. *Acta Oncologica* 2021; 60(4): 334–343.

On the occasion of Brno Oncology Days, Prof. Steffensen will deliver an invited lecture on the topic “Shared-decision making process and its implementation in daily practice – experience from Denmark”.

Diagnostic and treatment centres in MMCI

The MMCI has **22 diagnostic and treatment centres**, which focus on different cancer types, treatment procedures or supportive care services. Treatment centres deliver comprehensive cancer care based on interdisciplinary teamwork of specialist physicians and other non-medical healthcare professionals.

The concept of treatment centres enables us to provide **high-quality medical services** to MMCI patients and to share our expertise with other healthcare institutions within the region. Furthermore, MMCI provides **access to the most innovative diagnostics** and cancer treatment options including **robotic surgery, theranostics, precision oncology and radiotherapy**.

Breast Cancer Centre

Centres for Gastrointestinal tumors

- Centre for Oesophageal and Gastric Cancer
- Colon Cancer Centre
- Centre for Liver and Biliary Tract Cancer
- Centre for Pancreatic Cancer

Centres for Urologic tumors

- Prostate Cancer Centre
- Kidney and Urinary Tract Cancer Centre
- Testicular Cancer Centre

Centres for Gynecologic tumors

- Centre for Ovarian, Tubal and Peritoneal Cancers
- Centre for Uterine, Cervical and Vulvar Cancers

Centre for Lung and Pleural Cancer

Centre for Skin Cancer and Melanoma

Centre for Brain and Spinal Cord Tumours

Head and Neck Cancer Centre

Sarcoma centre

Centre for Neuroendocrine Tumours

Thyroid Cancer Centre



Centre for cancer of unknown primary and other rare malignancies

Centre for Precision Oncology

Robotic Surgery Centre

Centre for Palliative Medicine and Pain Management

Centre for cytoreduction and regional chemotherapy



Masaryk Memorial Cancer Institute



Masaryk Memorial Cancer Institute (MMCI) is **the largest cancer centre in the Czech Republic** in terms of the number of primarily treated adult patients with solid tumors and the provision of preventive cancer care. **Almost 5 000 newly diagnosed cancer patients** start treatment in MMCI every year. MMCI currently plays the role of the National cancer centre in the network of Czech Comprehensive Cancer Centres.

MMCI is an internationally recognized Institute, an accredited member of **the Organisation of European Cancer Institutes (OECI)** and **ESMO Designated Centre of Integrated Oncology and Palliative Care**. MMCI is also a member of ERN network for rare adult solid cancers EURACAN and for genetic tumor risk syndromes GENTURIS.

MMCI serves as a national node of the **BBMRI-ERIC** research infrastructure for biobanking and is a partner of Czech Clinical Research Infrastructure Network (CZECRIN).

MMCI is providing **health care services, research and education** in the areas of prevention, diagnosis and treatment of solid tumors. MMCI is affiliated to Masaryk University, within which it cooperates with two other university hospitals: University Hospital Brno and St. Anne's University Hospital. MMCI operates its own facility for basic and translational research called **RECAMO** (Research Centre for Applied Molecular Oncology) and provides full support for **clinical research, including Phase I Clinical Trial Unit**, biobanking and precision oncology programme.

